Siqian Lan

Dr. Siqian Lan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SLSiqian Lan
Siqian Lan
ZZZhengyan Zhao
Zhengyan Zhao
ZHZhixu He
Zhixu He
With the enhancement of public living standards and health awareness, demands for high-quality treatment with hematological malignancies are increasing, correspondingly. However, since significant adverse events have been found associated with chemotherapy, radiotherapy and other traditional anticancer measures, and a considerable number of patients still experience relapse or drug resistance, developing new treatment strategies has become the focus in the field of hematological malignancies. The measles virus vaccine strain, as an oncolytic virus, has been paid special attention to, due to its dual advantages of selectively invading and killing tumor cells and activating anti-tumor immunity. Currently, multiple studies have shown the effectiveness of unmodified measles virus vaccine strains in treating hematological malignancies. However, due to the systemic invasiveness and complexity of hematological malignancies, the concept of genetically engineered measles virus vaccine strain has garnered significant attention. In this article, we reviewed the progress on measles virus vaccine strains in the treatment of hematological malignancies, especially on the application of genetic engineering technology. Meanwhile, we also explored the challenges encountered in current treatments and discussed future design direction for modifying measles virus vaccine strains.

26 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
SLSiqian Lan
Siqian Lan
XHXiaoqiang Hao
Xiaoqiang Hao
DZDongming Zhou
Dongming Zhou
JPJinkai Peng
Jinkai Peng
ZZZhengyan Zhao
Zhengyan Zhao
Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their clinical translation remains limited, with Toll-like receptor (TLR)-mediated host immune responses representing a critical influencing factor. TLRs constitute a family of structurally conserved transmembrane proteins distributed on the plasma membrane and endosomal membranes. They initiate innate immune responses by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and are essential for dendritic cells (DCs) maturation, playing a pivotal regulatory role across diverse tumor therapies. However, TLRs may also restrict viral replication and spread, and some studies suggest that they could, under certain conditions, act as drivers of tumor progression. Nonetheless, the role of TLRs in OVT has not been comprehensively summarized to date. In this review, we synthesize recent advances in the application of TLRs in OVT, with particular attention to their mechanisms of action and the challenges that remain to be overcome, and consider their prospects in oncology, offering insights that may inform the clinical translation of this therapeutic approach.